Cellomics and BD Sign License Agreement to Further Expand Availability of High Content Screening
Pittsburgh, PA and San Jose, CA (November 9, 2004) -- Cellomics, Inc., the creator of High Content Screening (HCS), and global medical technology company BD (Becton, Dickinson and Company), through its BD Biosciences unit, announced today that they have entered into a non-exclusive, worldwide patent license agreement. The agreement will provide BD with Cellomics’ core High Content Screening patent portfolio that includes both broad claims to HCS technology and specific classes of HCS assays such as cytoplasm-nuclear translocation, characterization of cellular toxicity, and receptor internalization. Financial details of the agreement were not disclosed.
Financial details of the agreement were not disclosed.
“We are very pleased to be working with BD to further expand the adoption and availability of high content screening technology. Through licensing of our HCS patent portfolio, we are seeking to enable customers to more effectively address complex biological questions,” commented William T. Sharp, Cellomics’ Vice President of Business Development.
“With the recent acquisition of Atto Biosciences, and our licensing of this intellectual property from Cellomics, BD Biosciences extends our commitment to the area of high-content cellular analysis and strengthens our considerable capabilities in the area of live cell research that include high-resolution imaging, flow cytometry and a broad array of reagent systems," added Mark Lewis, Vice President of BD Biosciences.
“Completion of this second significant licensing arrangement of our HCS patent portfolio with a global company like BD confirms the value of our extensive intellectual property in this critical area of drug discovery and reaffirms our intent to facilitate the expansion of the HCS market via an aggressive licensing and commercial strategy,” stated Daniel J. Calvo, Cellomics’ President and CEO.
About BD
BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry, and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. For the fiscal year ended September 30, 2004, BD reported revenues of $4.935 billion.
About BD Biosciences
A business segment of BD, BD Biosciences (www.bdbiosciences.com) is one of the world’s largest businesses supporting the life sciences and is organized into four units: Clontech, Discovery Labware, Immunocytometry Systems, and Pharmingen. BD Biosciences provides high-quality products and services to accelerate discovery and diagnosis in the life sciences.
About Cellomics
Cellomics, Inc is automating drug discovery through a unique, cell-based assay platform that addresses the needs of Drug Discovery and Systems Biology groups by offering complete systems for High Content Screening. Cellomics’ proprietary HCS instruments, software, and assays are in use worldwide in pharmaceutical, biotechnology, and academic institutions.
For further information, contact:
Cellomics:
Judy P. Masucci, Ph.D.
Director of Marketing
Cellomics, Inc.
100 Technology Drive
Pittsburgh, PA 15219
412-770-2200 x 2353
412-770-2450 (fax)
BD:
Colleen T. White
Corporate Communications
201-847-5369
Phil Vanek
Director of Marketing
301-340-7320 x 226
Home 
Cellomics and BD Sign License Agreement to Further Expand Availability of High Content Screening
top